- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 1,843 of 2,219.
| EudraCT Number: 2020-001479-34 | Sponsor Protocol Number: SB16-3001 | Start Date*: 2020-11-10 | |||||||||||
| Sponsor Name:Samsung Bioepis Co., Ltd. | |||||||||||||
| Full Title: A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Compare the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity between SB16 (proposed denosumab biosimilar... | |||||||||||||
| Medical condition: Postmenopausal osteoporosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: LT (Completed) DK (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-000212-25 | Sponsor Protocol Number: HGT-HIT-046 | Start Date*: 2012-01-05 | |||||||||||
| Sponsor Name:Shire HGT Inc | |||||||||||||
| Full Title: An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase® in Pediatric Pati... | |||||||||||||
| Medical condition: Treatment of Hunter syndrome and cognitive impairment | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-014476-21 | Sponsor Protocol Number: CONKO-007 | Start Date*: 2013-02-22 | |||||||||||
| Sponsor Name:Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. med. Markus F. Neurath | |||||||||||||
| Full Title: Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer -a randomised phase 3 trial: Chemoradiation following induction chemotherapy compared with chemo... | |||||||||||||
| Medical condition: Locally advanced non resectable pancreatic cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-000588-26 | Sponsor Protocol Number: MK-8591A-019 | Start Date*: 2020-03-02 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | |||||||||||||
| Full Title: A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doraviri... | |||||||||||||
| Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-004984-31 | Sponsor Protocol Number: DR180133 | Start Date*: 2021-04-21 |
| Sponsor Name:CHRU TOURS | ||
| Full Title: Nitrous Oxide in Resistant Depression in Elderly Subjects: A Randomized, Double-blind, Comparator Trial | ||
| Medical condition: Resistant Depression in the Elderly Subject | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-002121-30 | Sponsor Protocol Number: 1704R2133 | Start Date*: 2020-04-17 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Shionogi B.V. | ||||||||||||||||||||||||||||||||||||||
| Full Title: An Open-label Study with a Nonrandomized Single-dose Phase in Subjects with Suspected or Confirmed Aerobic Gram-negative Bacterial Infections followed by a Randomized, Multiple-dose, Active-control... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Single dose: Pneumonia, cUTI, complicated intra-abdominal infections [cIAI], hospital acquired bacterial pneumonia [HABP]/ventilator-associated bacterial pneumonia [VABP], and sepsis or bloodstream... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: LT (Completed) GR (Completed) CZ (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-000296-21 | Sponsor Protocol Number: APHP191110 | Start Date*: 2020-04-09 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP) | |||||||||||||
| Full Title: Rapid rEcognition of COrticosteroid Resistant or sentive Sepsis RECORDS A Multicentre Concealed‐Allocation Multi-arms Blinded Randomized Controlled Trial to Identify the Best Sepsis Population for ... | |||||||||||||
| Medical condition: Patients admitted to the ICU proven or suspected infection as the main diagnosis. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004909-41 | Sponsor Protocol Number: NA | Start Date*: Information not available in EudraCT | ||||||||||||||||
| Sponsor Name:Akershus University Hospital Trust (HF) | ||||||||||||||||||
| Full Title: PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy: A Randomized, Placebo-controlled, Multicenter Trial | ||||||||||||||||||
| Medical condition: Prevention of cardiac dysfunction during adjuvant breast cancer treatment with anthracycline containing chemotherapy, with or without radiation or trastuzumab. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: NO (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-003942-35 | Sponsor Protocol Number: APHP200018 | Start Date*: 2021-04-27 | |||||||||||
| Sponsor Name:Assistance Publique - Hôpitaux Paris | |||||||||||||
| Full Title: HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency | |||||||||||||
| Medical condition: Critically ill patients with a SOFA score (SOFA; Sequential Organ Failure Assessment) ≥ 6, for at least 6 consecutive hours, suffering from CIRCI, to the notable exception of patients with septic s... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002464-75 | Sponsor Protocol Number: 534 | Start Date*: 2022-12-06 | |||||||||||
| Sponsor Name:Groupe Hospitalier Paris Saint-Joseph | |||||||||||||
| Full Title: Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial | |||||||||||||
| Medical condition: Acute exacerbation of idiopathic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005193-26 | Sponsor Protocol Number: P160407 | Start Date*: 2022-04-25 |
| Sponsor Name:ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (AP-HP) | ||
| Full Title: 18F]–Fludarabine PET/MR imaging for the assessment of newly-diagnosed primary central nervous system (CNS) lymphoma: a pilot PET/MR study | ||
| Medical condition: Patients with newly diagnosed primary lymphoma of the central nervous system who have not been treated with surgery, radiotherapy or chemotherapy. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-003034-16 | Sponsor Protocol Number: FNOL-IVA-ICD | Start Date*: 2014-05-12 |
| Sponsor Name:University Hospital Olomouc | ||
| Full Title: Antiarrhythmic and antiremodelation effects of ivabradin in ICD carriers | ||
| Medical condition: Heart failure | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-005494-11 | Sponsor Protocol Number: VERI-LONG | Start Date*: 2023-03-14 | |||||||||||
| Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
| Full Title: A parallel-group treatment, phase 2a, double-blind, placebo-controlled 2-arm study to show improvement of physical function in SF-36 (SF-36-PF) in participants treated with Vericiguat compared to p... | |||||||||||||
| Medical condition: Post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of myalgic encephalomyelitis/chronic fatique syndrome (ME/CFS) criteria | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-004022-30 | Sponsor Protocol Number: AKB-6548-CI-0041 | Start Date*: 2022-03-02 | ||||||||||||||||
| Sponsor Name:Akebia Therapeutics, Inc. | ||||||||||||||||||
| Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ONCE DAILY ORAL VADADUSTAT FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE AFTER CONVERSION FROM... | ||||||||||||||||||
| Medical condition: Anemia of Chronic kidney disease (CKD) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: HU (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2021-003994-72 | Sponsor Protocol Number: AKB-6548-CI-0042 | Start Date*: 2022-03-02 | ||||||||||||||||
| Sponsor Name:Akebia Therapeutics, Inc. | ||||||||||||||||||
| Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ONCE DAILY ORAL VADADUSTAT FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE NAÏVE TO ERYTHROPOIES... | ||||||||||||||||||
| Medical condition: Anemia of Chronic kidney disease (CKD) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: HU (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-002936-55 | Sponsor Protocol Number: MSC-EB_2020 | Start Date*: 2021-08-11 |
| Sponsor Name:Masarykova univerzita | ||
| Full Title: Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II | ||
| Medical condition: Epidermolysis bullosa congenita | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: CZ (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004480-31 | Sponsor Protocol Number: PSIKET_001CZE | Start Date*: 2020-07-14 |
| Sponsor Name:Národní ústav duševního zdraví | ||
| Full Title: Psilocybin versus ketamine – fast acting antidepressant strategies in treatment-resistant depression | ||
| Medical condition: The study will include 60 patients with pharmaco-resistant depression (30 male, 30 female, aged 18–65). The basic inclusion criterion is the diagnosis of pharmaco-resistant moderate to severe depre... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: CZ (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-002449-39 | Sponsor Protocol Number: 42756493BLC2003 | Start Date*: 2020-07-10 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Inva... | |||||||||||||
| Medical condition: Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusi... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) PL (Trial now transitioned) BE (Completed) FR (Trial now transitioned) CZ (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003108-15 | Sponsor Protocol Number: UC-GIG-2003 | Start Date*: 2022-11-04 | |||||||||||
| Sponsor Name:UNICANCER | |||||||||||||
| Full Title: A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function Score | |||||||||||||
| Medical condition: Hepatocellular Carcinoma (HCC), Child-Pugh B, ALBI grade 1 or 2 liver function | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-001604-17 | Sponsor Protocol Number: APHP220428 | Start Date*: 2022-11-15 | |||||||||||
| Sponsor Name:Assistance Publique - Hôpitaux de Paris | |||||||||||||
| Full Title: Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers | |||||||||||||
| Medical condition: Patients With Acute Heart Failure and Elevated Inflammatory Markers in Emergency Department | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.